Intermittent Explosive Disorder Terminated Phase 4 Trials for Naratriptan (DB00952)

IndicationStatusPhase
DBCOND0030738 (Intermittent Explosive Disorder)Terminated4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00282165Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order